CURRICULUM VITAE



 CURRICULUM VITAE

Name: YI-ZARN WANG, BDS, MD, FACS

 

Business Address: 200 W. Esplanade, Suite 200

Kenner, Louisiana 70065

Business Telephone and Telefax: (504) 464-8500/Office; (504) 464-8525/Fax

Business Email Address: ywang@lsuhsc.edu; yizarn@

 

Home Address: 1032 Clipper Drive, Slidell, LA 70458

Home Telephone: (504) 606-6333/Cell

 

Birthplace: Taiwan, Republic of China

Citizenship: U.S.A. (Naturalization date 2/11/98)

Naturalization Certificate No. 23474137

 

Education

Undergraduate:

1974 -1980 B.D.S. (Equivalent to D.D.S. in U.S.)

Kaohsiung Medical College, School of Dentistry Kaohsiung, Taiwan, Rep. of China

 

Graduate/Medical:

1982 – 1986 Certificate in Oral Pathology, Oregon Health

Sciences University, Department of Pathology Graduate/Residency Program, Portland, Oregon

 

1986 – 1990 M.D., Oregon Health Sciences University

School of Medicine, Portland, Oregon

Internship:

1990 - 1991 General Surgery, Washington University

School of Medicine/Barnes Hospital

Residency:

1990 – 1994 General Surgery, Washington University School of Medicine/Barnes Hospital

 

Post-Doctoral Fellowships:

1982 - 1986 Oral Pathology Resident, Department of Pathology, School of Dentistry, Oregon Health Sciences University, Portland, Oregon

 

1984 -1985 General Pathology Resident

  1987 Department of Anatomic Pathology, Veteran Administration Medical Center, Portland, Oregon

 

Clinical Fellowships:

1980 -1981 Postgraduate Hospital Dentistry Residency

The Air Force General Hospital

Taipei, Taiwan, Rep. of China

 Certification:

1990 National Board of Medical Examiners of the U.S., #387741

02/14/95 Diplomate of the American Board of Surgery

Certificate #39992 - Recertified October 17, 2004

  

 Licensure:

Louisiana, #10961R, 7/31/2012

Missouri, #106189 (Expired)

Academic, Professional, and Research Appointments

Academic Appointments:

1982 -1984 Teaching Assistant, Department of Pathology, School of Dentistry,

Oregon Health Sciences University, Portland, Oregon

 

1984-1985 Instructor, Patient Evaluation Clinic, Department of Clinical Pathology,

School of Dentistry, Oregon Health Sciences University, Portland, Oregon

 

1985 -1986 Lecturer, Sophomore General Pathology, Department of Pathology, School of Dentistry, Oregon Health Sciences University, Portland, Oregon

 

1985 -1986 Pathology Lab Instructor, Department of Pathology, School of Dentistry,

Oregon Health Sciences University, Portland, Oregon

 

1990-1991 Clinical Assistant Professor, Department of Pathology,

School of Dentistry, Oregon Health Sciences University

Portland, Oregon

1990 -1994 Teaching Assistant, Department of Surgery

Washington University School of Medicine, St. Louis, Missouri

1994 -1995 Instructor of Surgery, Department of Surgery

Louisiana State University Medical Center, School of Medicine

New Orleans, LA

 

1995 -2001 Assistant Professor of Surgery, Department of Surgery

Louisiana State University Health Sciences Center, School of Medicine

New Orleans, LA

 

2001 - Associate Professor of Surgery, Department of Surgery

12/2005 Louisiana State University Health Sciences Center, School of Medicine

New Orleans, LA

 04/2002- Director of Surgical Education, Department of Surgery

12/2005 Louisiana State University Health Sciences Center, School of Medicine

New Orleans, LA

 

09/2002- Chief, Division of General Surgery, Department of Surgery

12/2005 Louisiana State University Health Sciences Center, School of Medicine

New Orleans, LA

10/2005- Visiting surgeon and teaching staff, Department of

6/2006 Surgery, VAMC/Baylor College of Medicine, Houston, TX

07/2006- Associated Professor, Department of Surgery, Louisiana State University

6/2010 Health Sciences Center, School of Medicine

New Orleans, LA

10/2006- Staff Surgeon, Neuroendocrine Tumor Clinic, Ochsner-Kenner Medical

Present Center, Kenner, LA

7/2010- Professor of Surgery, Department of Surgery, Louisiana State University

Present Health Sciences Center, School of Medicine

New Orleans, LA

Research Appointments:

1985 -1986 Research Fellow

Department of Immunology, School of Dentistry

The Oregon Health Sciences University,

Portland, Oregon

Membership in Professional Organizations:

  American College of Surgeons, Fellow

Greater Louisiana Association of Endocrinologists

James D. Rives Surgical Society

Surgical Association of Louisiana

The Society for Surgery of the Alimentary Tract

Society of Laparoendoscopic Surgeons

American Society of Colon and Rectal Surgeons

American Hepato-Pancreato-Biliary Association

Society of Surgical Oncology

 

Awards and Honors:

1974 -1980 Scholarship sponsored by the Taiwan Sugar Corporation

 

1974 -1980 Scholarship from The Taiwan National Teacher’s Association

 

1980 “Award of Kaohsiung Medical College Alumina

Association in Japan”---received at my commencement from Kaohsiung Medical College, School of Dentistry

1982 -1985 Teaching Assistant Scholarship sponsored by Department of

Pathology, School of Dentistry, Oregon Health Sciences

University, Portland, Oregon

1996 Runner-up of Aesculapiaan Society Teaching Award – LSUHSC/NO

 

1997, 1998, Candidate for Allen Copping Teaching Award – LSUHSC/NO

1999, 2001

 

2001 Semi-Finalist for the Allen Copping Teaching Award – LSUHSC/NO

 

2003 Winner of the Allen Copping Teaching Award - LSUHSC/NO

2006 Nominee for Allen Copping Teaching Award - LSUHSC/NO

The residents have continued to nominate me yearly, although I am no longer eligible to be the award recipient since 2006.

Teaching Experience/Responsibilities

Course/Clerkship/Residency or Fellowship/CME Directorships: 

I was appointed as the course director of the weekly Basic Science and Clinical Surgical Review Conferences and was in charge of weekly teaching conferences from 11/1996 to 9/2005. I reviewed different surgical topics with the residents and students every week. I was appointed Director of Surgical Education from 4/2002 until 12/2005. I was selected to be the speaker at the weekly conferences more than 90% of the time, at the request of residents. The residents’ in-service exam score averages improved from 33% before I assumed the teaching assignment, to greater than 55% after I became the course director and weekly lecturer. The in-service exam scores remained above 50% for seven years in a row and during that time I was nominated for a teaching award every year. Additionally, the residents named the weekly conference “Wang’s conference”, which was approved by Department head.

 

On my own time, I engaged in detailed discussion about different General Surgery/Oncologic Surgery topics with individual residents who needed reinforcement of his or her knowledge base in clinical application, in-service, and board examination preparations. Each graduating chief resident who I worked with has passed their board exam. I also helped several chief residents who had already graduated prepare for their third and last chance to pass the boards, which they all did.

 

Curriculum Development/Implementation:

Once I was put in charge of the weekly teaching conferences, I changed the teaching format. My method involved a group discussion that was centered around one central topic and a set of well-organized questions I generated weekly to complement this topic. This style of teaching was different from the traditional lectures with handouts or slide presentations. The discussions were designed to merge the basic science concepts with clinical practice, and to move from the easy questions (to which the students and junior residents should know the answers) to those questions that even chief residents would struggle with.

Weekly, with one chosen topic, we began with simple questions in the area of anatomy and normal physiology, then moved on to a set of slightly more complex patho-physiology questions and finally to differential diagnosis and clinical workup. These discussions led to questions of appropriate treatment options, surgical versus nonsurgical approaches, operative intervention and possible expected and unexpected intra-operative findings, and finally the way to handle these different intra-operative observations. Conferences concluded with questions related the patients’ post–operative care including potential complications, follow-up visits and preventative processes including family member screenings.

This new format was well received by the students and residents. It was clearly reflected by the unmarked evaluations submitted by the residents biannually.

Creation of Enduring Teaching Materials:

My lecture notes have been stored in many residents' personal computers and are still being passed from residents to residents.

Formal Course Responsibilities:

I hosted and conducted weekly basic and clinic science conferences from 11/1996 to 1/2006. After hurricane Katrina I drove back and forth between Houston, OKL and UMC to teach residents and help them prepare for in-service and board exams.

Departmental/Interdisciplinary Conferences: 

Before Katrina, I routinely participated in the weekly grand rounds and M&M conferences. Often, I would be asked to make the final comments on different subjects or to answer questions from the audience that the invited speaker or presenters were not able to address or answer.

 

I attended the weekly multidisciplinary tumor conference and functioned as moderator.

 

I saw patients in the Charity Oncology Clinic with the students and residents on the Surgical Oncology Services every Wednesday afternoon. At the conclusion of clinic activities, I always reviewed interesting and important subjects in detail with the residents and students pertaining to one or a few patient conditions that we had encountered. Many times, I would review multiple topics in one afternoon.

 

Two days a week, I performed surgery on oncology patients with residents and students. I routinely conducted extensive teaching in the operating room while waiting for induction of anesthesia and/or during operation.

 

Three times a week, I conducted bedside rounds with students and residents; each round lasted about two hours to assure that we could have detailed discussion on different topics related to patient care.

 

Special Clinical Rounds: 

In addition to my own weekly conferences and all other teaching activities, I frequently functioned (50%) as the substitute host for Dr. J. Patrick O'Leary to conduct the weekly Chairman’s Rounds. In such conferences, I would dissect and discuss the index case with students and residents.

 

I also frequently served as a substitute host for Dr. Isidore Cohn, Jr., to run the weekly students’ “Cohn's Conference” when he had other commitments. Together, students and I would review three cases and discuss the presenting symptoms and signs of patients. We then generated a list of differential diagnoses and considered the potential diagnostic workups. Once the diagnosis was established, we then discussed different treatment options, which led to the best and most logical therapeutic planning.

After Katrina, while I was detailed to the VAMC/Baylor College of Medicine in Houston, TX, I continued to conduct my weekly conferences in Baton Rouge and Lafayette. In order to do so, I had to drive back and forth between Houston and New Orleans every week for more than three months until the in-service exam was over in January of 2006. I was very pleased to learn that the residents did well on the exam that year despite the distraction from Katrina. To show their appreciation, the residents as a group submitted a joint letter to Dr. O’Leary to nominate me for the Allen Copping teaching award for the year of 2006 and pleaded for my return to be an active teaching faculty member again.

Currently, we hold case discussion rounds at OMCK biweekly to discuss patient management for difficult neuroendocrine tumor cases. I continue to teach the residents and students rotating on our service in the clinic, bedside, and operating room.

The residents’ in-service exam score, as a whole, has continued to decline yearly since I stepped down from the weekly teaching post. Per the residents’ request, I resumed the monthly “Wang conference” in June of 2011. Residents have requested the conference now as a weekly event, currently pending departmental chair approval.

Grants and Contracts

Funded:

1999 - 2004 Co-investigator, NSABP B-30 - A Three-Arm Randomized Trial to Compare Adjuvant Adriamycin/Cyclophosphamide Followed by Taxotere (AC-T); Adriamycin and Taxotere (AT); and Adriamycin, Taxotere and Cyclophosphamide (ATC) in Breast Cancer Patients With Positive Axillary Lymph Nodes (Trial opened to accrual 3/15/1999; closed to accrual 3/31/2004)

 

  2000 - 2005 Co-investigator, NSABP B-31 - A randomized trial comparing the safety and efficacy of Adriamycin and Cyclophosphamide followed by Taxol (AC-T) to that of Adriamycin and Cyclophosphamide followed by Taxol plus Herceptin (AC-T+H) in Node Positive Breast Cancer Patients who have Tumors that over express HER2 (Trial opened to accrual 2/21/2000; closed to accrual 4/29/2005)

 

  2000 - 2002 Co-investigator, NSABP C-07 - A Clinical Trial Comparing 5-Fluoriuracil

(5FU) Plus Leucovorin (LV) and Oxaliplatin with 5-FU plus LV for the Treatment of Patients with Stages II and III Carcinoma of the Colon (Trial opened to accrual 2/1/2000; closed to accrual 11/15/2002)

 

  2000 – 2004 Co-investigator, NSABP B-34 - A Clinical Trial Comparing Adjuvant

Clodronate Therapy vs. Placebo In Early-Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Tamoxifen or No Therapy (Trial opened to accrual 12/1/2000; closed to accrual 3/31/2004)

  

2001-2002 Co-investigator of A Prospective, Multicenter, Double –Blind with In-House blinding, Randomized, Comparative Study to Evaluate the Efficacy, Safety, and Tolerability of Ertapenem Sodium Versus Piperacillin/Tazobactam in the Treatment of Complicated Intra-Abdominal Infections in Hospitalized Adults

2001 - 2004 Co-investigator of A Multicenter, Randomized, Double Blind, Comparative Trial of Intravenous MerremTM (meropenem, ICI 119,660) vs Primaxin® I.V. (imipenem-cilastatin) in the Treatment of Hospitalized subjects with Complicated Skin and Skin Structure Infections.

  

2001 - 2003 Co-investigator, NSABP B-33 - A Randomized, Placebo-Controlled, Double-Blind Trial Evaluating The Effect of Exemestane in Clinical Stage T1-3 N0-1M0 Postmenopausal breast Cancer Patients Completing At Least

Five Years of Tamoxifen Therapy -and- Bone Mineral Density, Biochemical Markers, and Lipid (BBL) Sub-Study of NSABP B-33 (Trial opened to accrual (Trial opened to accrual 5/1/2001; closed to accrual 10/9/2003)

 

2001 - 2002 Co-Investigator of J4A-MC-EZZI (a): A Phase IIb Study to Determine the

Efficacy and Safety of LY315920 in Patients with Severe Sepsis

2002 - 2005 Co-Investigator of A Prospective, Multicenter, Double-Blind With In

house Blinding, Randomized, Comparative Study to Evaluate the Efficacy, Safety, and Tolerability of Ertapenem versus Piperacillin/Tazobactam in the Treatment of Diabetic Foot Infections in Adults

2003 – 2009 Co-Investigator, NSABP B-35 – A Clinical Trial Comparing Astrozole with

Tamoxifen in Postmenopausal Patients with Ductal Carcinoma in Situ (DCIS) Undergoing Lumpectomy with Radiation Therapy (Trial opened to accrual 1/6/2003)

 

2004 - 2005 Co-Investigator. NSABP B-36 – A Clinical Trial of Adjuvant Therapy

Comparing Six Cycles of 5-Fluroouracil, Epirubicin and Cyclophosphamide [FEC] to four Cycles of Adriamycin and Cyclophosphamide [AC], with or without Celecoxib, in Patients with Node-Negative Breast Cancer (Trial opened to accrual 5/20/2004)

 

2004 – 2008 Co-Investigator, NSABP B-38 – A Phase III, Adjuvant Trial Comparing Three Chemotherapy Regiments in Woman with Node-Positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide followed by DD Paclitaxel (DD AC→P); DD AC followed by DD Paclitaxel plus Gemcitabine (DD AC→PG) (Trial opened to accrual 10/1/2004)

2004 – 2009 Primary/Co-Investigator, IND 70,627- Feasibility of One-Step Sentinel Lymph Node (SLN) Biopsy with Radiolabeled Methylene Blue

2006 - Co-Investigator. The angiogenesis potential of different neuroendocrine tumors and the angiogenesis capacity difference between the primary and metastasis in different anatomic locations.

2006 – 2009 Co-Investigator. The correlation between the level of plasma/urine tumor markers in patients with neuroendocrine tumors and the degree of their surgical debulking.

2006 - Co-investigator. The correlation between the level of plasma/urine tumor markers in patients with neuroendocrine tumors and the usage of Hydrogen pumps inhibitors.

2006 – 2009 Co-investigator. The chemoresistance of different neuroendocrine, and the chemoresistance difference between the primary and different anatomic neuroendocrine tumor metastasis. Data collected and presented as abstract and has been published.

2006 - Sponsor: Novartis Pharmaceuticals                    

Co-Investigator. An Open Label, Stratified, Single-Arm Phase II study of RAD001 in patients with Advanced Pancreatic Neuroendocrine Tumor (NET) After Failure of Cytotoxic Chemotherapy.

 

2006 - Sponsor: Novartis Pharmaceuticals                    

Co-Investigator. A Randomized, Double-Blind, Placebo-Controlled, Multi-center Phase III study in Patients with Advanced Carcinoid Tumor Receiving Sandostatin LAR and RAD001 10mg/day or Sandostatin LAR and Placebo.

 

2009 - Sponsor: Novartis Pharmaceuticals                    

Co-Investigator. A Randomized, Double-Blind, Phase III study of RAD001 10mg/day Plus Best Supportive Care in the Treatment of Patients with Advanced Pancreatic Neuroendocrine Tumor (NET).

2011- Co-investigator. IMCL CP13-0710: A Phase 2, Multicenter, Two-Tier Study of IMC-A12 in Combination with Depot Octreotide in Patients with Metastatic, Well- or Moderately- Differentiated Carcinoid or Islet Cell Carcinoma.

Non-funded applications:

2006 – 2008 Primary Investigator. The utility of Sentinel Lymph Node Identification Technology in the surgical management of patients with advanced neuroendocrine tumors.

2006 – 2008 Primary Investigator. The long-term outcome of aggressive mesenteric lymph node debulking in surgical management of patients with advanced neuroendocrine tumor.

2006 – 2009 Primary Investigator. The utility of Lymphatic Mapping Technology in the surgical management of patients with advanced neuroendocrine tumors.

2006 – 2009 Primary Investigator. The incidence of diaphragmatic tumor implants in patients with advanced neuroendocrine tumors and their treatment outcome.

2006 – 2010 Primary Investigator. The application of Radioguided Surgical Technology in the surgical management of patients with advanced neuroendocrine

tumors.

2006 – 2010 Primary Investigator. New innovative pre- video assist thorascopic surgery technique using combination of blue dye and TC-99 Colloid

2006 – 2009 Primary Investigator. Development of a new easy technique for a staged second look laparoscopy to evaluate post-op bowel ischemia following extensive mesenteric lymphadenectomy for midgut carcinoid

2006 - Primary Investigator. The long-term outcome of aggressive liver resection and/or tumor ablation in surgical management of patients with advanced neuroendocrine tumor. Work in progress and data collection ongoing. Invitational publication for a special edition from International Journal of Hepatology.

2006 - Primary Investigator. The long-term outcome of aggressive mesenteric lymphadenectomy and resection of primary carcinoid cancer in patients with massive un-resectable liver metastasis. Work in progress and data collection ongoing. Invitational publication for a special invitation from Cancers

2006 - Primary Investigator. Intra-operative chemotherapy for advanced carcinoid patients following liver enucleation, resection and or mesenteric lymphadenectomy. Work in progress and data collection ongoing.

2008-2011 Primary Investigator. Cervical and upper mediastinal lymph node metastasis from gastrointestinal and pancreatic neuroendocrine tumors.

2009-current Primary Investigator. Radioisotope and blue dye mapping for rectal carcinoid to define proximal margin and detect extra-mesorectal nodes

Inventions and Patents:

1). I am the first surgeon to apply lymphatic mapping to define surgical resection margins and sparing the ileocecal valve, when conditions permit, for patients with midgut carcinoid cancer. I was granted an opportunity to have an oral presentation of my work at the 2009 American Association of Endocrine Surgeons (AAES) annual meeting in Madison, WI. It was well received by more than three hundred surgeons from different academic institutions around the world. As a result of that presentation, I have received four invitations to be a visiting speaker at various hospitals, universities and organizations.

Wang YZ, Joseph S, Lindholm E, Lyons J, Boudreaux JP, Woltering EA. Lymphatic mapping helps define resection margins for midgut carcinoids. Surgery. 2009 Dec, 146(6): 993-7.

2). I invented an easy way to conduct a staged second look laparoscopy to evaluate ischemic bowel after extensive lymphadenectomy for mid gut carcinoid cancer.

Wang YZ. Second-Look Laparoscopy to Evaluate Ischemic Bowel. JSLS. 2009 Oct-Dec, 13(4): 560-3.

3) Another invention of mine is a new technique using both blue dye and TC-99 colloid to tattoo a pulmonary nodule before video assisted thoracic surgery.

Wang YZ, Boudreaux JP, Dowling A and Woltering EA. Percutaneous localisation of pulmonary nodules prior to video assisted thoracoscopic surgery using Methylene blue and TC-99 ---A new modification of existing techniques. Eur J Cardiothoracic Surg. 2010 Jan, 37(1): 237-8.

4) I am the first surgeon to become proficient in a technique using a radiolabeled blue dye for one stage sentinel lymph node biopsy for breast cancer in a phase I/II trial.

Cundiff JD, Wang YZ, Espenan G, Maloney T, Camp A, Lazarus L, Stolier A, Brooks R, Torrance B, Stafford S, O'Leary JP, Woltering EA. A phase I/II trial of 125I methylene blue for one-stage sentinel lymph node biopsy. Ann Surg. 2007 Feb;245(2):290-6.

5). I first recognized that neuroendocrine patients who presented with neck and upper mediastinal lymph node metastasis are always on the left side. I further studied the incidence, clinical implication and their optimal treatment option. I am the first surgeon to use radio-guided minimally invasive surgery to address carcinoid metastasis in the lower neck and upper mediastinum.

Wang YZ, Mayhall G, Anthony L, Campeau R, Boudreaux JP, and Woltering EA. Cervical and upper mediastinal lymph node metastasis from gastrointestinal and pancreatic neuroendocrine tumors: The true incidence and their management. American College of Surgeons Clinical Congress, San Francisco, CA. (2011)

6) I am the first surgeon to make link between pulsatile tinnitus and external tumor compression on extra-cranial vessels and be able to resolve it with minimally invasive surgical procedure.

Wang YZ, Boudreaux JP, Campeau R, and Woltering EA. Resolution of pulsatile tinnitus following an upper mediastinum lymph node resection. Southern Medical Journal. 2010 Apr, 103(4): 374-7.

7). I have designed a new technique using Neoprobe and TC-99 to define proximal surgical margins for rectal malignancy. Data collection is ongoing and soon I should have the first series to report. This will be the first report of this nature and it might revolutionize the conventional surgical resection of rectal cancer.

8) I am the first surgeon who uses intra-operative chemotherapy for patients with advanced carcinoid cancer whose resection margin in the liver or mesentery vessels might be inadequate. Soon, I should have the first serial patients to report and this will be the first report in this nature and it might revolutionize the conventional surgical approach to advanced carcinoid cancer or cancer in general. Data collection in progress.

9) I am the first physician to make and report the observation that diaphragmatic implants from midgut carcinoid are always located on the right side and its clinical implication. Poster presented at 2009 SSO meeting.

Lyons III JM, Lindholm E, Boudreaux JP, Anthony LB, Woltering EA, Wang YZ. Diaphragmatic Implants in Patients with Metastatic Carcinoid.  The Society of Surgical Oncology 62nd Annual Cancer Symposium. Phoenix, AZ (2009).

10) I am the first surgeon to become proficient in a technique using a hand held gamma detector to facilitate the cytoreduction surgeries for patients with neuroendocrine tumors.

Wang YZ, Gandolfi AE, Anthony LB, Campeau R, Woltering E, and Boudreaux JP. Radio-guided exploration facilitates surgical cytoreduction of neuroendocrine tumors. LA Chapter of American College of Surgeons. New Orleans, LA. (2010)

Wang YZ, Gandolfi AE, Anthony LB, Campeau R, Woltering E, and Boudreaux JP. Radio-guided exploration facilitates surgical cytoreduction of neuroendocrine tumors. AAES. Pittsburgh, PA. (2010)

Wang YZ, Gandolfi AE, Anthony LB, Campeau R, Woltering E, and Boudreaux JP. Radio-guided exploration facilitates surgical cytoreduction of neuroendocrine tumors. NANETS Conference. Santa Fe, NM. (2010)

Wang YZ, Gandolfi AE, Anthony LB, Campeau R, Woltering E, and Boudreaux JP. Radio-guided exploration facilitates surgical cytoreduction of neuroendocrine tumors.

Journal of Gastrointestinal surgery. 2011 Nov 22. [Epub. ahead of print] PMID:22105237

11) I am the first surgeon to recognize and report the unique and unusual final pathway for some long term carcinoid patients.

Yi-Zarn Wang DDS., MD and Heather King MD

Cocoon formation in patients with Mid-gut neuroendocrine tumors---a rare and unrecognized final pathway. NANETS Conference, Minneapolis, MN. (2011)

12) I first recognized that obturator cannel lymph node metastasis associated with rectal carcinoid that would be missed with the conventional Total mesorectal excision.

Yi-Zarn Wang DDS., MD and Michael Hall MD, MS

Obturator canal lymph node metastasis from rectal carcinoid tumor---Total mesorectal excision may be insufficient for some rectal carcinoids.

ASCO/2012 Gastrointestinal cancer symposium, San Francisco, California, January 19-21, 2012

Yi-Zarn Wang DDS., MD and Michael Hall MD, MS

Obturator canal lymph node metastasis from rectal carcinoid tumor---Total mesorectal excision may be insufficient for some rectal carcinoids.

Society of Surgical Oncology’s 65th annual cancer symposium, Orlando, Florida, March 21-24, 2012

13). I report that high incidence of lymph node metastasis in small size rectal carcinoid and recommending revision of treatment guideline for rectal carcinoid cancer.

Yi-Zarn Wang DDS., MD, Anne Diebold BS, Philip Boudreaux MD, Daniel Raines MD., Richard Campeau MD, Lowell Anthony MD and Eugene Woltering MD.

Surgical treatment options for rectal carcinoid cancer: Trans-anal excision Versus Low Anterior Resection with Total Mesorectal Excision.

Oral presentation, SAGES 2012 annual meeting, San Diego, California, March 7-10, 2012

14). I am currently collecting data regarding to the incidence of ovarian metastasis among women with Gastrointestinal Neuroendocrine tumors and the association of these metastasis and the development of carcinoid syndrome and carcinoid heart disease, in order to address the optimal treatment including the consideration of prophylactic oophorectomy.

15). I am currently collected all chemo-resistance assays on all patients operated on for a neuroendocrine tumor in order to modify and develop new intra-operative chemotherapy measures.

16). I am investigating the incidence of an “unknown primary” among patients who have biopsy proven neuroendocrine tumors seen at our clinic, the treatments offered, and the treatment out comes.

17). I am in process of developing a treatment strategy to address carcinomatosis for neuroendocrine patients.

18). I am reviewing data to see if resection of a primary functioning pancreatic neuroendocrine tumor would reduce or improve patient’s clinic symptoms in light of the existence of their untreated liver metastasis.

19). I am in process of reviewing our surgical experience of aggressive debulking of more than four hundred patients with advanced gastrointestinal neuroendocrine tumors.

20). I am developing new novel usage of irreversible electroporation (IRE) in conjunction with intraoperative local chemotherapy.

21). I am planning to alter our current surgical treatment strategy by utilizing tissue diagnosis, pathological grading, genetic profiling, chemo-resistance and angiogenesis assays all the above mentioned data into our surgical explorations and intra/post operative adjuvant therapy.

22). I am in process of revising surgical technique in surgical debulking of liver metastasis from neuroendocrine tumors.

Invited Presentations:

Oral presentation, AAES Annual Meeting: Lymphatic mapping helps define resection margins for midgut carcinoids, Madison, WI. May 3-5, 2009.

Invited Speaker, Lymphatic mapping helps define resection margins for midgut carcinoids, Neuroendocrine patient conference. New Orleans, September 24-26, 2009

Oral presentation, ACS Annual Chapter Meeting: Radioguided Exploration Facilitates Surgical Cytoreduction of Neuroendocrine Tumors, New Orleans, January 2010.

Invited speaker, Denver Colorado Carcinoid cancer patients support group: Surgical treatment of Carcinoid- What’s new? Denver, Co, September 11, 2010.

Invited speaker, NOIDS in Carolinas Carcinoid cancer patients support group: Surgical treatment of Carcinoid- What’s new? Charlotte, NC, November 14, 2010

Visiting professor / Grand round: Surgical treatment of Carcinoid- What’s new?

Mount Sinai Medical School/ Medical Center, New York, May 18, 2011.

Invited speaker, Virginia medical association: Surgical treatment of Carcinoid-what’s new? White Stone Creek, Virginia, May 19, 2011.

Oral Presentation, SAGES Annual Meeting: Surgical treatment options for rectal carcinoid cancer: Trans-anal excision Versus Low Anterior Resection with Total Mesorectal Excision. San Diego, California, March 7-10, 2012

Invited speaker, International carcinoid /NET conference: Surgical treatment of Intestinal Neuroendocrine tumors-what’s new & what’s next? Ottawa, Ontario, Canada, May 4-6, 2012.

 

University/Institutional Service

LSUHSC (campus) committees:

Cancer Education Committee

  The Moses Maimonides Award for Ethics in Medicine Committee

  Women Veterans Advisory Committee (Surgical Services)

  Careers in Medicine Course

  Committee in Residents’ Education - LSUHSC

  

Clinical Service

In-patient service activities:

Before Katrina, I ran the Surgical Oncology Service for almost 10 years and performed major oncology procedures with chief residents, junior residents, and students on the service. I am also involved in patient care at University’s General Surgery Service. I provide assistance to other surgeons at Charity Hospital or VAMC in performing complex oncological procedures.

Since October 2006, I have joined the physician group serving neuroendocrine tumor patients at Ochsner-Kenner Medical Center. I have teamed up with Dr. Phil Boudreaux to establish a unique surgical team, a transplant surgeon and a surgical oncologist, performing highly complex surgical procedures for patients who suffer from advanced neuroendocrine tumors independently or as a team as indicated. Our team has been well respected and loved by patients and their family members throughout the country and abroad as well. We have been named by patients as a dream team for carcinoid cancer patients. With the promotion from our patients in cyber space, we have seen an increasing number of patients from different states and even other countries.

Currently, we have established a well-known neuroendocrine tumor treatment center. On average, I conduct 3-4 major cyto-reductive surgeries (lymphatic mapping guided resection of small bowel primary, extensive mesenteric lymphadenectomy to open the encased major mesenteric vessels, liver resection, retroperitoneal aorto-caval lymph node dissection, pancreatic or colorectal resection) for our patients who come from all over the country. In the last five years together I have performed more than 600 major surgeries for patients with neuroendocrine tumors. At this point, our surgical team has become the most experienced team around the world in dealing with such a rare and unique disease. While providing the best surgical care to our patients, I also have initiated many clinical research activities and implemented and/or invented many new surgical approaches or modifications. I have been presenting my works in national and international meetings in the last three years (AAES, 2009, 2010; ACS, 2010, 2011; NANETS, 2008, 2009, 2010, 2011)

Administrative Responsibilities

Departmental: Director of Surgical Education until 12/2005, Resident advisor

School of Medicine: Student Preceptor

Hospital: Member of the Pharmacy & Therapeutics/Infection

Control Committee, Ochsner-Kenner medical center

Book Chapters:

 

1. Seza A. Gulec, Yi-Zarn Wang, Randolph B. Reinhold, Frederick J. Doherty and Frank M. Mele. Chapter 26. Selected Technologies in General Surgery. In O’Leary (ed)’s The Physiologic Basic of Surgery, Third edition, Lippincott Williams & Wilkins. 2002.

 

2. Kennan J Buechter, Yi-Zarn Wang, John P. Hunt, Sharon Weintraub. Chapter 9. Kinematic of Trauma. In Moore, Mattox, Feliciano (eds) Trauma, Fifth edition. McGraw Hill, 2004.

3. Sharon L Weintraub, Yi-Zarn Wang, John P Hunt, J. Patrick O’Leary. Chapter 10. Principles of Preoperative and Operative Surgery.  Sabiston Textbook of Surgery, 17th edition. Elsevier Saunders 2004.

 

 Videos and Multimedia

1. “Rite of Passage” Trauma care documentary series---“Code Blue”, Charity Hospital, New Orleans, The Learning Channel, 2001.

 

2. “Close calls” Trauma care documentary series---“Code Blue”, Charity Hospital New Orleans, The Learning Channel, 2002.

 

3. “Critical Hour” Trauma care documentary series, Charity Hospital, New Orleans, The Discovery Health Channel, 2004.

 

Journal Publications

1. Bullock WW, Wang YZ, Gabler WL, and Creamer HR. Aggregate human colostral sIgA stimulates delayed, non-complement-dependent NBT reduction by

human neutrophils. Inflammation 1989; 13(1):67-78.

2. Wang, YZ. Surgical intervention for hyperparathyroidism: preoperative localization with/without intraoperative localization/biological PTH assay versus

surgeon’s brain and hands. Current Surgery 1995; 52(1):15-20.

3. Wang, YZ, Flattman G., Steeb G., O’Leary J.P. Surgical management of perforated duodenal ulcer. Surgical Rounds 1998; Supplement (11):4-11.

4. Steeb G., Wang Y.Z., O’Leary J.P. Management of perforated peptic ulcers. Hospital Practice special report. Sept. 1998.

5. Wang Y, Wang S: Automation of clinical and patient records. Southern Medical

Journal 1999; 92(1): 16-22.

6. Meyers MO, Gagliardia AR, Flattmann JG, Wang YZ, and Woltering EA: Suramin Analogues Inhibit Human Angiogenesis In Vitro. Journal of Surgical Research, 2000; 91(2): 130-134.

7. Steeb G, Wang YZ, Siegrist B, O’Leary JP: Infections within the peritoneal

cavity: a historical perspective. Am Surg 2000, Feb; 66(2):98-104.

8. Hunt JP, Wright MJ, Steeb G., Wang YZ, Buechter KJ, Meyer AA, Baker CC. Accuracy of administrative data in trauma: splenic injuries as an example. J. Trauma 2000; 49(4): 679-686.

9. Wynn A., Wise M, Wright MJ, Rafaat A, Wang Y, Steeb G, McSwain N, Buechter KJ, Hunt JP. Accuracy of Administrative & Trauma Registry databases.

J Trauma 2001:51;464-8.

10. Wang YZ, and Wang S. The digital signature technology for health care applications. Southern Medical Journal, 2001.Mar;94(3): 281-6.

11. Phelan H, Hunt J, and Wang YZ: Management of retrohepatic caval injury. Southern Medical Journal, 2001; Jul; 94(7); 728-31.

12. Jung SP, Siegrist B, Hornick CA, Wang YZ, Wade JR, Anthony CT, Woltering EA. Effect of human Recombinant Endostatin protein on Human Angiogenesis.

Angiogenesis 2002; 5:111-118.

13. Duchesne JC, Wang YZ, Weintraub SL, Boyle M, Hunt JP. Stoma complications: a multivariate analysis. Am Surg. 2002 Nov, 68(11)961-6; discussion 966.

14. Maxwell IV PJ, Lewis JM, Anthony CT, Watson JC, Meyer5s MO, Espenan TD,

Espenan GD, Wang YZ, Woltering EA. External Bean Radiation Therapy Does

Not Inhibit the Human “Angiogenic Switch” But Decreases Endothelial Cell Growth and Angiogenic Vessel Development. Ann Surg Onc, Suppl to January 2003: 10:1, S49.

15. Woltering EA, Lewis JM, Maxwell PJ, Frey DJ, Wang YZ, Rothermel J, Anthony CT, Balster DA, O’Leary JP, Harrison LH. Development of a Novel in Vitro Human Tissue-Based Angiogenesis Assay to Evaluate The Effect of Antiangiogenic Drugs. Annals of Surgery, 2003, 237(6);790-800.

16. Lewis JM, Grafton LH, Maxwell IV PJ, Martin LF, Nesbit LT, Wang Y-Z, Woltering EA. Development of an Architecturally-Intact Human Skin-Based Angiogenesis Model. JACS, Suppl September 2003: 197:3, S57.

17. Cooke HJ, Wang YZ, Wray D, O’Dorisio MS, Woltering EA, Coy DH, Murphy WA, Christofi FL, Gosh P, O’Dorisio TM. A multi-tyrosinated sst1/2 receptor preferring somatostatin agonist inhibits reflex and immune-mediated secretion in

the guinea pig colon. Regulatory Peptides, 2003 Jun 15, 114(1); 51-60.

18. Siegrist B, Anthony CT, Hornick C, Wade MR, Jung SP, Wang YZ and Woltering EA. Effect of human Angiostatin protein on human angiogenesis in vitro. Angiogenesis. 2003; 6(3): 233-40.

19. Ghanami R, Obeid L, Buchert B, Beech S, Wang YZ, Lopez FA. Clinical case of

the month. Expanding abdominal mass in a 41-year-old patient with a history of alcohol abuse. J La State Med Soc. 2004 Jul - Aug;156(4):181-5.

20. Lewis JM, Maxwell IV PJ, Anthony CT, Gebhardt BM, Thompson JL, Rothermel J, McSheehy P, Wang YZ, Woltering EA. Epothilone B is a More Potent Antiangiogenic than Paclitaxel in a Human Tumor-Based Angiogenesis Model. JACS, Suppl. Oct, 2004;199: S90.

21. Gulec SA, Weintraub S, Wang YZ, Cundiff J, Albarado R, Moulder P, O'Leary JP, Hunt JP. Gamma-guided diagnostic peritoneal lavage for detection of bowel perforation. Arch Surg. 2004 Oct, 139(10):1075-8.

22. Stafford SJ, Schwimer J, Anthony CT, Thomson JL, Wang YZ, Woltering EA. Colchicine and 2-methoxyestradiol Inhibit Human Angiogenesis. J Surg Res. 125(1):104-8. 2005

23. Stafford SJ, Wright JL, Schwimer J, Anthony CT, Cundiff JD, Thomson JL, Wang YZ, Espenan G, Maloney T, Camp A, Woltering EA. Development of 125I-methylene blue for sentinel lymph node biopsy. J Surg Oncol. 2006 Sep 15;94(4):293-7.

24. Cundiff JD, Wang YZ, Espenan G, Maloney T, Camp A, Lazarus L, Stolier A, Brooks R, Torrance B, Stafford S, O'Leary JP, Woltering EA. A phase I/II trial of

125I methylene blue for one-stage sentinel lymph node biopsy. Ann Surg. 2007 Feb;245(2):290-6.

25. Duchesne JC, Hunt JP, Wahl G, Marr AB, Wang YZ, Weintraub SE, Wright MJ,

McSwain NE Jr. Review of current blood transfusions strategies in a mature level

I trauma center: were we wrong for the last 60 years? J. Trauma. 2008 Aug;65(2):272-6; discussion 276-8.

26. Lyons JM III, Abergel J, Thomson J, Anthony CT, Wang YZ,  Anthony L, Boudreaux JP , Strauchen J, Idrees M, Warner R, and Woltering EA. In Vitro Chemoresistance Testing in Well-Differentiated Carcinoid Tumors. Ann Surg Oncol. 2009 Mar; 16(3): 649-655.

27. Lyons JM III, Schwimer JE, Anthony CT, Thomson JL, Cundiff JD, Casey DT,

Maccini C, Kucera P, Wang YZ, Boudreaux JP, Woltering EA. The Role of VEGF Pathways in Human Physiologic and Pathologic Angiogenesis. J. Surg. Res. 2010 Mar, 159(1): 517-27.

28. Wang YZ, Boudreaux JP, Dowling A, and Woltering EA. Percutaneous localization of pulmonary nodules prior to video assisted thoracoscopic surgery using Methylene blue and TC-99 ---A new modification of existing techniques. Eur J Cardiothoracic Surg. 2010 Jan; 37(1): 237-8.

29. Wang YZ, Joseph S, Lindholm E, Lyons J, Boudreaux JP, Woltering, EA. Lymphatic mapping helps define resection margins for midgut carcinoids. Surgery. 2009 Dec; 146(6): 993-7.

30. O’Dorisio TM, Krutzik SR, Woltering EA, Lindholm E, Joseph S, Wang YZ, Boudreaux JP, Vinik AI, Go VLW, Howe JR, Halfdanarson T, O’Dorisio SM, and Mamikunian G. Development of a Highly Sensitive and Specific Carboxy- terminal Human Pancreastatin Assay to Monitor Neuroendocrine Tumor Behavior. Pancreas. 2010 Jul; 39(5): 611-6.

31. Wang YZ. Staged Second-Look Laparoscopy to Evaluate Ischemic Bowel. JSLS. 2009 Oct-Dec; 13(4): 560-3.

32. Wang YZ, Boudreaux JP, Campeau R and Woltering EA. Resolution of pulsatile

tinnitus following an upper mediastinum lymph node resection. South Med J. 2010 Apr; 103(4): 374-7.

33. Joseph S, Wang YZ, Boudreaux JP, Anthony LB, Campeau R, Raines D, O’Dorisio TM, Go VLW, Vinik AI, Cundiff J, and Woltering EA: Neuroendocrine Tumors: Current Recommendations for Diagnosis and Surgical Management. Endocrinol Metab Clin N Am. 2011 Mar; 40(1): 205-31.

34. Anthony CT, Bastidas JG, Thomson JL, Lyons J 3rd, Lewis JM, Schwimer JE, Casey P, Abadie J, Frey DJ, Wang YZ, Boudreaux JP, Woltering EA. A study of pipeline drugs in neuroendocrine tumors. J Gastrointest Cancer. 2011 May. DOI:

10.1007/s12029-011-9286-9

35. Brashear J, Ryan P, Wang YZ, Anthony LB, Boudreaux JP, Joseph S, Campeau R, Woltering EA. A prospective evaluation of the value of intensive pre-visit counseling in patients with neuroendocrine tumors (NETS). The American surgeon. 2012; 78(1):43-4.

36. Wang YZ, Diebold AE, Anthony LB, Campeau R, Woltering E, and Boudreaux JP. Radio-guided exploration facilitates surgical cytoreduction of neuroendocrine tumors. J Gastrointest Surg. 2012;16(3):635-640.

37. Wang YZ and MD Patrick Greiffenstein P. Foreign Body Ingestion Unmasks Latent Small Bowel Carcinoid Tumor. Case Report and Review of the Literature.

Clinics and Practice 2012; 1(2). DOI: 10.4081/cp.2012.e2

38. Lindholm E, Lyons J, Anthony C, Boudreaux JP, Wang YZ, Woltering E. Do Primary Neuroendocrine Tumors and Metastasis Have the Same Characteristics? J of Surgical Research. Accepted

39. Wang YZ, Mayhall G, Anthony L, Campeau R, Boudreaux JP, and Woltering EA. Cervical and upper mediastinal lymph node metastasis from gastrointestinal and pancreatic neuroendocrine tumors: The true incidence and their management.

American College of Surgeons. Accepted.

41. Wang YZ and King H. Cocoon formation in patients with midgut neuroendocrine tumors---a rare and unrecognized final pathway. American Surgeon. Submitted.

42. Wang YZ, Diebold A, Boudreaux JP, Raines D, Campeau R, Anthony L and Woltering E. Surgical treatment options for rectal carcinoid cancer: Trans-anal excision Versus Low Anterior Resection with Total Mesorectal Excision. Journal of Surgical Endoscopy. Submitted.

40. Woltering EA, Diebold AE, Wang YZ, Anthony LA, Boudreaux JP, Uhlhorn AP, Ryan P, Burns LAK, Frey D, Raines D, Majoria R, and Campeau R. Treatment of Small Bowel Neuroendocrine Tumors (NETs) in a Multidisciplinary Specialty Center Increases Survival. Work In Progress.

43. Wang YZ and Hall M. Obturator canal lymph node metastasis from rectal carcinoid tumor---Total mesorectal excision may be insufficient for some rectal carcinoids. Work in progress.

Abstracts:

1. Flattmann G, Meyers MO, Alperinlea RC, Woltering EA and Wang Y. A Novel Human Vascular Whole Organ Modification of the Boyden Chamber. The Society of University Surgeons Resident’s Program. Tampa, FL. (1997)

2. Wang Y-Z, O’Dorisio TM, O’Dorisio MS, Woltering EA, Coy DH, Murphy WA, Gosh P, Cooke HF: Multi-Tyrosinated Somatostatin Analog, WOC–3B, Inhibits Histamine H2 Receptor-Mediated Cyclical Chloride Secretion in the Guinea Pig Colon. AGA. (1997)

3. Wang Y-Z, Alferes L, O’Dorisio TM, O’Dorisio MS, Woltering EA, Coy DH, Murphy WA, Gosh P, Cooke HJ: Role of Somatostatin Receptors in Discriminating Between Mechanosensitive Release of 5-HT and PGE2 in the Initiation of Secretory Reflexes in the Guinea Pig Colon (1997)

4. Cooke HJ, Wang YZ, Alferes L, O’Dorisio TM, O’Dorisio MS, Woltering EA, Coy DH, Murphy WA, and Ghosh P: Release of Paracrine Mediators Initiating Secretory Reflexes is Differentially Regulated by a Somatostatin Analog in the Guinea Pig Colon. International Symposium on Regulatory Peptides. (1998)

5. Hunt J, Buechter KJ, Wang Y. Solid Organ Injuries: Liver, Spleen & Kidney. Pediatric Trauma Conference (Statewide). New Orleans, LA. (1998)

6. Meyers MO, Gagliardia AR, Flattman GJ, Wang YZ, Woltering EA. Suramin Analogues Inhibit Human Angiogenesis in Vitro. Association for Academic Surgery Annual Meeting. (1999)

7. Hunt JP, Wright MJ, Wang Y, Steeb G, Buechter KJ, Meyer A and Baker CC. The Accuracy of Administrative Data in Trauma Spleenic Injuries as an Example. American Association for the Surgery of Trauma. Boston, MA. (1999)

8. Meyers MO, Gagliardia AR, Flattmann GJ, Wang YZ, and Woltering EA. Suramin Analogues Inhibit Human Angiogenesis in Vitro. Association for Academic Surgery, 33rd Annual Meeting. Philadelphia, PA. (1999)

9. Wynn A, Wise MW, Wright MJ, Rafaat A, Wang YZ, Steeb G, McSwain N, Buechter KJ, Hunt J. The Accuracy of Administrative and Trauma Registry Databases. East Association for Surgery of Trauma. (2001)

10. Lazarus L, Wynn S, Gordon JM, Steeb G, Wang YZ, Buechter, JK, O’Leary JP, Hunt JP. Risk Factors for Abdominal Wound Dehiscence. The Louisiana Chapter of the American College of Surgeons. New Orleans, Louisiana. (2001)

11. Lazarus L, Wynn A, Gordon JM, Steeb G, Wang YZ, Buechter KJ, O’Leary JP, Hunt JP. Risk Factors for Abdominal Wound Dehiscence. The Society of University Surgeons. Chicago, Illinois. (2001)

12. Francis DE, Anthony CJ, Wang YZ, Woltering EA. Alpha-Interferon Inhibits Human Angiogenesis, in Vitro. Society of University Surgeon’s Residents’ Program. Chicago, Illinois. (2001)

13. Masse PA, Anthony CJ, Wang YZ, Woltering EA. Bi-directional Chemoattraction: The role of vessels and tumors. Society of University Surgeon’s Residents’ Program. Chicago, Illinois. (2001)

14. Duchesne JC, Wang YZ, Weintraub SL, Boyle M, Hunt JP. Stoma Complications: A Multivariate Analysis. Presented at the Louisiana Chapter of the American College of Surgeons Annual Meeting. New Orleans, Louisiana. (2002)

15. Woltering EA, Maxwell PJ, Lewis JM, Harrison LH, Frey DJ, Wang YZ, Rothermel J, Anthony CT, O’Leary JP. Development of a novel in Vitro human

tumor-based angiogenesis assay to evaluate the effect of Antiangiogenic drugs on

individual patient tumors. Southern Surgical Association. (2002)

16. Maxwell IV PJ, Lewis JM, Anthony CT, Watson JC, Meyers MO, Espenan TD, Espenan GD, Wang YZ, Woltering EA. External beam radiation therapy does not inhibit the human “angiogenic switch” but decreases endothelial cell growth and angiogenic vessel development. Society of Surgical Oncology. (2003)

17. Lewis JM, Grafton LH, Maxwell IV PJ, Martin LF, Nesbitt LT, Wang YZ, Woltering EA. Development of an architecturally-intact human skin-based angiogenesis model. American College of Surgeons Surgical Forum. Chicago, IL. (2003)

18. Kaplan JL, Bronaugh H, Ortiz W, Gonzalez A, Lopera J, Hunt JP, Wang YZ, Weintraub S. Treatment of portal vein thrombosis with direct thrombolytic infusion via an operatively placed mesenteric catheter. Annual Meeting of The Southeastern Surgical Congress. (2004)

19. Lewis JM, Maxwell IV PJ, Anthony CT, Gebhardt BM, Thompson JL, Rothermel J, McSheehy P, Wang YZ, Woltering EA. Epothilone B is a More Potent Antiangiogenic than Paclitaxel in a Human Tumor-Based Angiogenesis Model. Surgical Forum. (2004)

20. Allain BW Jr., Stafford SJ, Lewis JM, Schwimer JE, Anthony CT, Kucera PR, Maccini CA, Boudreaux JP, Frey DJ, Wang YZ, Woltering EA. In vitro analysis of the efficacy of 2-Methoxyestradiol on human tumor derived angiogenesis. LAAXS. New Orleans, LA. (2005)

21. Stafford SJ, Schwimer J, Anthony CT, Thomson JL, Wang YZ, Woltering EA.

Colchicine and 2-methoxyestradiol Inhibit Human Angiogenesis. Louisiana

Chapter of the American College of Surgeons Convention. (2005)

22. Schwimer J, Allain B, Rosedale B, Torrance B, Frey D, Boudreaux P, Anthony

CT, Anthony L, Wang YZ, Woltering EA. Effects of PTK787 on Angiogenesis in two ex-vivo models of angiogenesis. Louisiana Chapter of the American College

of Surgeons Convention. (2005)

23. Stafford SJ, Schwimer J, Anthony CT, Thomson JL, Wang YZ, Woltering EA. Effect of Two Anti-VEGF Directed Therapies on Human Angiogenesis In Vitro. Awarded 1st Place at the Louisiana Chapter of the American College of Surgeons Convention. (2005)

24. Stafford SJ, Schwimer J, Anthony CT, Thomson JL, Wang YZ, Woltering EA. Not All Angiogenic Vessels Are the Same: Effect of Two Somatostatin Analogs on Human Angiogenesis In Vitro. Louisiana Chapter of the American College of Surgeons Convention. (2005)

25. Lyons III, JM, Lindholm E, Anthony LB, Wang YZ, Woltering EA, Boudreaux JP. Metastatic carcinoid causing encasement of the mesenteric vasculature should not preclude cytoreduction. North American Neuroendocrine Tumor Society (NANETS) Annual Meeting. (2008)

26. Lyons III, JM, Lindholm E, Anthony LB, Boudreaux JP, Woltering EA, Wang YZ. Application of Sentinel Lymph Node Mapping in Abdominal Carcinoid Tumors. North American Neuroendocrine Tumor Society (NANETS) Annual Meeting. (2008)

27. Lyons JM, Abergel J, Wang YZ, Anthony LB, Boudreaux JP, Warner RRP, Woltering EA: In-Vitro Analysis of Chemo-resistance in Patients with “Typical” and “Atypical” Carcinoid Tumors. North American Neuroendocrine Tumor Society (NANETS) Annual Meeting. (2008)

28. Lyons, III JM, Abergel J, Thomson JL, Wang YZ, Anthony LB, Boudreaux JP, Strauchen J, Idrees M, Warner RRP, Woltering EA: In vitro chemoresistance testing in well differentiated carcinoid tumors. The Society of Surgical Oncology 61st Annual Cancer Symposium. Chicago, IL. (2008)

29. Lyons, III JM, Lindholm E, Boudreaux JP, Anthony LB, Woltering EA, Wang YZ. Diaphragmatic Implants In Patients With Metastatic Carcinoid.  The Society of Surgical Oncology 62nd Annual Cancer Symposium. Phoenix, AZ. (2009).

30. Wang YZ, Joseph S, Lindholm E, Lyons J, Boudreaux JP, Woltering EA. Lymphatic mapping helps define resection margins for midgut carcinoids. AAES (American Association of Endocrine Surgeons) annual Meeting. Madison, WI. (2009)

31. Wang YZ, Joseph S, Lindholm E, Lyons J, Boudreaux JP, Woltering EA. Lymphatic mapping helps define resection margins for midgut carcinoids. Neuroendocrine Patient Conference. New Orleans LA. (2009)

32. Wang YZ, Joseph S, Lindholm E, Lyons J, Boudreaux JP, Woltering EA. Lymphatic mapping helps define resection margins for midgut carcinoids. NANETS annual Meeting. (2009)

33. Lyons JM III, Lindholm E, Wang YZ, Thomson JL, Anthony LB, Woltering EA, Frey DJ, Joseph S, Ramacharan T and Boudreaux JP. Extensive retroperitoneal carcinoid involving the mesenteric vasculature does not preclude effective cytoreduction. NANETS annual Meeting. (2009)

34. Brashear J, Ryan P, Wang YZ, Anthony LB, Boudreaux JP, Joseph S, Campeau R and Woltering EA. Initial evaluation of patients with NETS: A prospective evaluation of intensive pre-visit counseling. NANETS annual Meeting. (2009)

35. Lyons III JM , Lindholm E, Thomson JL , Anthony LB, Woltering EA, Frey DJ, Joseph S, Ramacharan T, Wang YZ and Boudreaux JP. Extensive retroperitoneal carcinoid involving the mesenteric vasculature does not preclude effective cytoreduction. LA Chapter of American College of Surgeons. (2010)

36. Brashear J, Ryan P, Wang YZ, Anthony LB, Boudreaux JP, Joseph S, Campeau R and Woltering EA. Initial evaluation of patients with NETS: A prospective evaluation of intensive pre-visit counseling. LA Chapter of American College of Surgeons. (2010)

37. Wang YZ, Gandolfi AE, Anthony LB, Campeau R, Woltering E, and Boudreaux JP. Radio-guided exploration facilitates surgical cytoreduction of neuroendocrine tumors. LA Chapter of American College of Surgeons. New Orleans, LA. (2010)

38. Wang YZ, Gandolfi AE, Anthony LB, Campeau R, Woltering E, and Boudreaux JP. Radio-guided exploration facilitates surgical cytoreduction of neuroendocrine tumors. AAES. Pittsburgh, PA. (2010)

39. Wang YZ, Gandolfi AE, Anthony LB, Campeau R, Woltering E, and Boudreaux JP. Radio-guided exploration facilitates surgical cytoreduction of neuroendocrine tumors. NANETS Conference. Santé Fe, NM. (2010)

40. Wang YZ, Woltering E, and Boudreaux JP. Staged second-look laparoscopy to evaluate ischemic bowel following extensive mesenteric lymphadenectomy for midgut carcinoid. NANETS Conference. Santé Fe, NM. (2010)

41. Campeau RJ, Anthony LB, Woltering EA, Wang YZ, and Boudreaux JP. Short Term Response to Systemic I-131 MIBG Therapy in Metastatic Carcinoid Tumors. NANETS Conference. Santé Fe, NM. (2010)

42. Lindholm EB, Anthony C, Boudreaux JP, Gandolfi A, Ryan P, Wang YZ, Woltering EA. Are Primary Tumors and Metastatic Tumors the Same? NANETS Conference. Santé Fe, NM. (2010)

43. Wang YZ, Mayhall G, Anthony L, Campeau R, Boudreaux JP, and Woltering EA. Cervical and upper mediastinal lymph node metastasis from gastrointestinal and pancreatic neuroendocrine tumors: The true incidence and their management. American College of Surgeons Clinical Congress, San Francisco, CA. (2011)

44. Wang YZ, Mayhall G, Anthony L, Campeau R, Boudreaux JP, and Woltering EA. Cervical and upper mediastinal lymph node metastasis from gastrointestinal and pancreatic neuroendocrine tumors: The true incidence and their management. NANETS Conference, Minneapolis, MN. (2011)

45. Woltering EA, Diebold AE, Wang YZ, Anthony LA, Boudreaux JP, Uhlhorn AP, Ryan P, Burns LAK, Frey D, Raines D, Majoria R, and Campeau R. Treatment of Small Bowel Neuroendocrine Tumors (NETs) in a Multidisciplinary Specialty Center Increases Survival. NANETS Conference, Minneapolis, MN. (2011)

46. Diebold AE, Boudreaux JP, Wang YZ, Anthony LB, Uhlhorn AP, Ryan P, and Woltering EA. Neurokinin A Levels Predict Survival in Patients with Well Differentiated Small Bowel Neuroendocrine Tumors (NETs). NANETS Conference, Minneapolis, MN. (2011)

47. King H, Wang YZ. Cocoon Formation in Patients with Mid-Gut Neuroendocrine Tumors: A Rare and Unrecognized Final Pathway. NANETS Conference, Minneapolis, MN. (2011)

48. Jahangir KS, Majoria R, Hagan J, Boudreaux J, Wang YZ, Boulmay B, Campeau R, Woltering E, and Anthony L. Hepatic Artery Radioembolization (HARE) in the Management of Progressive Metastatic Neuroendocrine Tumors (NETs): A Survival and Biochemical Response Analysis in Geriatric (G) and Young (Y) Populations. NANETS Conference, Minneapolis, MN. (2011)

49. Wang YZ and Hall M. Obturator canal lymph node metastasis from rectal carcinoid tumor---Total mesorectal excision may be insufficient for some rectal carcinoids. ASCO/2012 Gastrointestinal cancer symposium, San Francisco, California. (2012)

50. Wang YZ, Diebold A, Boudreaux JP, Raines D, Campeau R, Anthony L and Woltering E. Surgical treatment options for rectal carcinoid cancer: Trans-anal excision Versus Low Anterior Resection with Total Mesorectal Excision. Oral presentation, SAGES annual meeting. San Diego, California. March 7-10, 2012

51. Wang YZ. King H. Cocoon Formation in Patients with Mid-Gut Neuroendocrine Tumors: A Rare and Unrecognized Final Pathway. SAGES annual meeting. San Diego, California. March 7-10, 2012

52. Wang YZ and Hall M. Obturator canal lymph node metastasis from rectal carcinoid tumor---Total mesorectal excision may be insufficient for some rectal carcinoids. Society of Surgical Oncology’s 65th annual cancer symposium, Orlando, Florida. March 21-24, 2012

53. Diebold AE, Boudreaux JP, Wang YZ, Anthony LB, Uhlhorn AP, Ryan P, and Woltering EA. Neurokinin A Levels Predict Survival in Patients with Well Differentiated Small Bowel Neuroendocrine Tumors (NETs). AAES Annual Meeting. Iowa City, IA. (2012)

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download